HNGE has spent the week after its debut earnings print doing something rare for a newly public digital health company: forcing bears to rethink while analysts scramble to lift targets.
The shift in short positioning is the clearest sign that the post-earnings narrative has turned. Short interest dropped 18% over the week to 9.7% of the free float — down from 11.8% ahead of the June 10 print — as roughly 820,000 borrowed shares were returned. That move follows a stock now up 8% on the week and 24% over the past month to $67.81. The unwind looks deliberate rather than forced. Borrow availability has loosened dramatically, reaching 3,116% — meaning there are now over thirty shares available to lend for every one currently borrowed, more than double the level from a week ago. Cost to borrow ticked up 21% on the week to 0.46%, but at that absolute level it remains cheap. The ORTEX short score has slid from 48.2 to 42.8 over the past eight sessions, reflecting the combined effect of falling positions and a rising price. The lending market is not signalling a squeeze; shorts are simply stepping back.
Options traders are not adding much drama. The put/call ratio is running at 0.48, marginally below its 20-day average of 0.50 — slightly call-heavy if anything, and less defensive than it was during the build-up to earnings. The z-score of -0.73 confirms nothing extreme in either direction. The 52-week range on PCR runs from 0.14 to 1.86, so the current reading lands squarely in neutral territory. Taken together, the positioning picture looks like a measured re-rating rather than a crowded momentum chase.
The Street has moved quickly and decisively in the same direction. At least eight firms raised price targets in the past week alone — a coordinated post-earnings lift that is hard to dismiss as noise. Keybanc moved to $90, Truist to $85, and Raymond James to $80, all while keeping positive ratings. Barclays and RBC both lifted targets to the $70–$75 range with Overweight and Outperform calls intact. The lone exception in tone is Baird, which raised its target from $55 to $65 but held at Neutral — a meaningful gap to the $67.81 close that keeps one firm effectively on the sidelines. The consensus mean target is $79.73, implying roughly 18% further upside from current levels. The bull case centres on AI-driven MSK care, cost savings for payers, and margin expansion; bears point to the high cost of retention, execution risk in new verticals like migraine, and a valuation — PE near 23x, PB near 12x — that leaves little room for missteps. EPS momentum scores rank in the 94th percentile on both 30- and 90-day windows, but the growth factor score is weak, a reminder that this remains a show-me story on profitability.
The insider and institutional picture adds a note of caution. Bessemer Venture Partners, a 10%-plus holder, sold nearly $13 million worth of shares across three transactions between June 1 and June 12. Co-founder and Executive Chairman Gabriel Mecklenburg sold roughly $3.3 million in the same window. The 90-day net insider position is a net sell of nearly $57 million in value — a figure that reflects the broader pattern of early backers monetising at levels they find attractive. Atomico added 2.3 million shares in its most recent filing, and RTW Investments built a new position of 1.58 million shares as of March quarter-end, so institutional appetite is not uniformly negative. But the insider-selling cadence is consistent and worth tracking as the lock-up period evolves.
The next scheduled earnings event is August 5. Between now and then, the key question is whether the short-covering seen this week runs its course or whether fresh sellers re-engage near the analyst target cluster in the $75–$85 range.
See the live data behind this article on ORTEX.
Open HNGE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
